Abdera Therapeutics, a Menlo Park, CA and Vancouver, Canada-based biopharmaceutical company that provides an antibody engineering ROVEr platform, raised $142M in Series A and Series B funding.
Versant Ventures and Amplitude Ventures led the Series A round, with participation from Northview Ventures as well as founding partners of Abdera, adMare BioInnovations and AbCellera. The Series B round was led by venBio Partners with participation from existing investors as well as new investors including Viking Global Investors, Qiming Venture Partners USA and RTW Investments.
The company intends to use the funds to expand operations and its &D efforts with its lead program targeting DLL3 for small cell lung cancer and other solid tumors advancing toward clinic.
Led by CEO Lori Lyons-Williams, Abdera Therapeutics is a biopharmaceutical company that leverages antibody engineering to design and develop new precision radiopharmaceuticals for cancer. Its Radio Optimized Vector Engineering (ROVEr) platform allows the company to design potential therapies for both clinically validated and novel targets that deliver potent radioisotopes capable of emitting alpha or beta particles to selectively destroy cancer cells. Its core program targets DLL3 for the treatment of small cell lung cancer and other solid tumors.
bdera’s executive team includes:
- Lori Lyons-Williams, president and chief executive officer
- Adam Judge, Ph.D., co-founder and senior vice president, research
- Lana Janes, Ph.D., co-founder and senior vice president, operations and innovation
- Michael Abrams, Ph.D., co-founder and senior advisor
- Kawa Chiu, chief technical officer
- Jennifer McNealey, chief financial officer
- Alison Armour, M.D., FRCR, FRCP, interim chief medical officer
- Kelly Parker, senior vice president, human resources
Abdera’s board of directors includes:
- Garry Nicholson, independent director and chairman of the board
- Joel Drewry, Ph.D., principal, Versant Ventures
- Nancy Harrison, venture partner, Amplitude Ventures
- Maria Koehler, M.D., Ph.D., chief medical officer, Repare Therapeutics
- Colin Walsh, Ph.D., partner, Qiming Venture Partners USA
- Yvonne Yamanaka, Ph.D., principal, venBio Partners
- Lori Lyons-Williams, president and chief executive officer
FinSMEs
24/04/2023